Search Results - "Klippel, Zandra"

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA‐HIGH‐RISK CYTOGENETICS: ICARIA‐MM AND IKEMA SUBGROUP ANALYSIS by Moreau, Philippe, Perrot, Aurore, Dimopoulos, Meletios A., Martin, Thomas, Facon, Thierry, Eduardo Capra, Marcelo, Beksac, Meral, Armstrong, Nicole, Dubin, Franck, Macé, Sandrine, Risse, Marie‐Laure, Tekle, Christina, Klippel, Zandra, Richardson, Paul

Get full text

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) by Pinter, Tamás, Klippel, Zandra, Cesas, Alvydas, Croitoru, Adina, Decaestecker, Jochen, Gibbs, Peter, Hotko, Yevhen, Jassem, Jacek, Kurteva, Galina, Novotny, Jan, O'Reilly, Seamus, Salek, Tomas, Reiner, Maureen, Morrow, Phuong Khanh, Choi, Mi Rim, Whittaker, Sadie, Blanke, Charles

“…In a phase III, double-blind trial, 845 patients with advanced colorectal cancer receiving bevacizumab plus first-line chemotherapy (FOLFOX [leucovorin),…”
Get full text

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA‐MM AND IKEMA STUDIES by Perrot, Aurore, Richardson, Paul, Mikhael, Joseph, Martin, Thomas G., Beksac, Meral, Spicka, Ivan, Eduardo Capra, Marcelo, D’agostino, Mattia, Sonneveld, Pieter, Bisht, Kamlesh, Fukao, Taro, Zhang, Rick, Tada, Keisuke, Tekle, Christina, Macé, Sandrine, Klippel, Zandra, Velde, Helgi, Moreau, Philippe

Get full text

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials by Moreau, Philippe, Stewart, Keith A., Dimopoulos, Meletios, Siegel, David, Facon, Thierry, Berenson, James, Raje, Noopur, Berdeja, Jesus G., Orlowski, Robert Z., Yang, Hui, Ma, Haijun, Klippel, Zandra, Zahlten‐Kumeli, Anita, Mezzi, Khalid, Iskander, Karim, Mateos, Maria‐Victoria

“…Combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered…”
Get full text

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation by Cowan, Andrew J., Klippel, Zandra K., Stevenson, Philip A., Hyun, Teresa S., Tuazon, Sherilyn, Becker, Pamela S., Green, Damian J., Holmberg, Leona A., Coffey, David G., Gopal, Ajay K., Libby, Edward N.

“…Introduction: High-dose melphalan and autologous stem cell transplantation (HDM/SCT) is an effective treatment modality for immunoglobulin light-chain (AL)…”
Get full text

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study by Dimopoulos, Meletios, Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Yang, Hui, Klippel, Zandra, Zahlten-Kumeli, Anita, Usmani, Saad Z

“…Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma…”
Get full text

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma by Facon, Thierry, Lee, Jae Hoon, Moreau, Philippe, Niesvizky, Ruben, Dimopoulos, Meletios, Hajek, Roman, Pour, Ludek, Jurczyszyn, Artur, Qiu, Lugui, Klippel, Zandra, Zahlten-Kumeli, Anita, Osman, Muhtarjan, Paiva, Bruno, San-Miguel, Jesus

“…The phase 3 CLARION study compared carfilzomib-melphalan-prednisone (KMP) with bortezomib-melphalan-prednisone (VMP) in transplant-ineligible newly diagnosed…”
Get full text

Blood-Based Mass Spectrometry MRD Tracking (M-InSight) in Multiple Myeloma Patients from Clinical Trial NCT02513186 by Di Stefano, Luciano, Mouktadi, Zarouki, Vimard, Victor, Moreau, Sarah, Mace, Sandrine, Klippel, Zandra K., Bonifay, Vincent, Rougé Dubroc, Caroline, Sonigo, Pierre

“…Multiple Myeloma (MM) is a type of cancer of the bone marrow characterized by an anormal growth of the number of plasma cells, which produce a monoclonal…”
Get full text

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim by Dale, David C., Crawford, Jeffrey, Klippel, Zandra, Reiner, Maureen, Osslund, Timothy, Fan, Ellen, Morrow, Phuong Khanh, Allcott, Kim, Lyman, Gary H.

“…Purpose Filgrastim (NEUPOGEN ® ) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related…”
Get full text

In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019 by Klippel, Zandra, Kimball, Amy, Tekle, Christina

Get full text

P-180 MRD Tracking in Blood Using a De Novo Sequencing From SPEP Gel of M-Protein in Multiple Myeloma Patients by Mouktadi, Zarouki, Stefano, Luciano Di, Vimard, Victor, Moreau, Sarah, Macé, Sandrine, Klippel, Zandra, Bonifay, Vincent, Rougé-Dubroc, Caroline, Sonigo, Pierre

Get full text

Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies by Li, Yanli, Klippel, Zandra, Shih, Xiaolong, Reiner, Maureen, Wang, Hong, Page, John H.

“…Purpose Chemotherapy-induced neutropenia (CIN) may increase infection risk for cancer patients; however, there is limited understanding on the quantitative…”
Get full text

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy by Li, Yanli, Klippel, Zandra, Shih, Xiaolong, Wang, Hong, Reiner, Maureen, Page, John H.

“…Purpose Risk of infection increases with severity and duration of chemotherapy-induced neutropenia (CIN). Pegfilgrastim is approved for use on the day after…”
Get full text

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma by Facon, Thierry, Dimopoulos, Meletios-Athanasios, Leleu, Xavier P., Beksac, Meral, Pour, Ludek, Hájek, Roman, Liu, Zhuogang, Minarik, Jiri, Moreau, Philippe, Romejko-Jarosinska, Joanna, Spicka, Ivan, Vorobyev, Vladimir I., Besemer, Britta, Ishida, Tadao, Janowski, Wojciech, Kalayoglu-Besisik, Sevgi, Parmar, Gurdeep, Robak, Pawel, Zamagni, Elena, Goldschmidt, Hartmut, Martin, Thomas G., Manier, Salomon, Mohty, Mohamad, Oprea, Corina, Brégeault, Marie-France, Macé, Sandrine, Berthou, Christelle, Bregman, David, Klippel, Zandra, Orlowski, Robert Z.

“…More patients treated with isatuximab, bortezomib, lenalidomide, and dexamethasone had improved progression-free survival and had a complete or better response…”
Get full text

Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): Frailty subgroup analysis from phase III ASPIRE and ENDEAVOR by Facon, Thierry, Niesvizky, Ruben, Weisel, Katja, Bringhen, Sara, Ho, P. Joy, Obreja, Mihaela, Yang, Zhao, Klippel, Zandra Karina, Blaedel, Julie, Mezzi, Khalid, Siegel, David Samuel DiCapua

“…Abstract only 8028 Background: K-based regimens improved progression-free survival (PFS) and overall survival (OS) in RRMM patients (pts) in ASPIRE (K [27 mg/m…”
Get full text

Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice by Li, Yanli, Family, Leila, Yang, Su-Jau, Klippel, Zandra, Page, John H, Chao, Chun

“…NCCN has classified commonly used chemotherapy regimens into high (>20%), intermediate (10%-20%), or low (<10%) febrile neutropenia (FN) risk categories based…”
Get more information

MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis by Moreau, Philippe, Perrot, Aurore, Dimopoulos, Meletios-Athanasios, Martin, Thomas, Facon, Thierry, Capra, Marcelo, Beksac, Meral, Armstrong, Nicole M, Pharm, Franck Dubin, Macé, Sandrine, Risse, Marie-Laure, Tekle, Christina, Klippel, Zandra, Richardson, Paul G.

“…UHR MM pts have even poorer prognosis than pts with no or 1 chromosomal abnormality (CA). Isa is an approved anti-CD38 monoclonal antibody that was evaluated…”
Get full text

POSTER: MM-182 Allocation and Validation of the Second Revision of the International Staging System in the ICARIA-MM and IKEMA Studies by Perrot, Aurore, Richardson, Paul, Mikhael, Joseph, Martin, Thomas, Beksac, Meral, Spicka, Ivan, Capra, Marcelo, D'Agostino, Mattia, Sonneveld, Pieter, Bisht, Kamlesh, Fukao, Taro, Zhang, Rick, Tada, Keisuke, Tekle, Christina, Macé, Sandrine, Klippel, Zandra, van de Velde, Helgi, Moreau, Philippe

Get full text

POSTER: MM-246 Isatuximab (Isa) in Relapsed Multiple Myeloma (MM) Patients (pts) With Ultra-High-Risk (UHR) Cytogenetics: ICARIA-MM and IKEMA Subgroup Analysis by Moreau, Philippe, Perrot, Aurore, Dimopoulos, Meletios-Athanasios, Martin, Thomas, Facon, Thierry, Capra, Marcelo, Beksac, Meral, Armstrong, Nicole M, Dubin, Franck, Macé, Sandrine, Risse, Marie-Laure, Tekle, Christina, Klippel, Zandra, Richardson, Paul G.

Get full text

MM-182 Allocation and Validation of the Second Revision of the International Staging System in the ICARIA-MM and IKEMA Studies by Perrot, Aurore, Richardson, Paul, Mikhael, Joseph, Martin, Thomas, Beksac, Meral, Spicka, Ivan, Capra, Marcelo, D'Agostino, Mattia, Sonneveld, Pieter, Bisht, Kamlesh, Fukao, Taro, Zhang, Rick, Tada, Keisuke, Tekle, Christina, Macé, Sandrine, Klippel, Zandra, van de Velde, Helgi, Moreau, Philippe

“…The International Staging System (ISS) underwent revision to include high-risk chromosomal abnormalities (R-ISS), and recently, to assign a score for each risk…”
Get full text